info@seagull-health.com
SeagullHealth
语言:
search
new
What Are the Side Effects of Astomin (Dimemorfan Phosphate Tablets)?
502
Article source: Seagull Pharmacy
Nov 17, 2025

Astomin (Dimemorfan Phosphate Tablets) is a non-narcotic central antitussive. Since its launch in Japan in 1975, it has been widely used to relieve cough symptoms in adults due to its low side effects and low abuse risk. Like all medications, it may be accompanied by adverse reactions and medication risks while exerting therapeutic effects.

What Are the Side Effects of Astomin (Dimemorfan Phosphate Tablets)?

Allergic Reactions

Some patients may experience skin rashes. The incidence rate is unclear, but close observation of skin changes is required in the early stage of medication.

Psychoneurological Reactions

Dizziness and drowsiness: Common central inhibitory effects that may affect the ability to drive or operate precision machinery.

Headache or heavy head sensation: Mostly transient, usually alleviating gradually with prolonged medication.

Fatigue and lassitude: May be related to the drug’s regulatory effect on nerve function.

Gastrointestinal Discomfort

Dry mouth and loss of appetite: Caused by the drug’s inhibition of glandular secretion; small sips of water frequently are recommended for relief.

Nausea, vomiting, and diarrhea: Mostly occur in the early stage of medication, usually mild and self-resolving.

Severe Side Effects of Astomin (Dimemorfan Phosphate Tablets)

Risk of Aggravated Allergic Reactions

If a rash progresses to urticaria, difficulty breathing, or mucosal edema, vigilance should be maintained for the possibility of anaphylactic shock, and immediate medical intervention is necessary.

Severe Neurological Abnormalities

Persistent drowsiness, confusion, or motor coordination disorders may indicate excessive central nervous system depression, requiring dosage adjustment or medication replacement.

Acute Cardiovascular Symptoms

If palpitations are accompanied by chest pain, syncope, or significant blood pressure fluctuations, the drug’s impact on the cardiac conduction system should be evaluated.

Precautions for Using Astomin (Dimemorfan Phosphate Tablets)

Standardized Administration Methods

PTP Packaging Warning: Tablets must be removed from the aluminum foil blister before taking. Accidental ingestion of the aluminum foil may cause its sharp edges to pierce the esophageal mucosa, leading to life-threatening complications such as perforation and mediastinitis.

Individualized Dosage: For adults (over 15 years old), the recommended dosage is 1–2 tablets (equivalent to 10–20mg dimemorfan phosphate) per dose, three times a day. Dosage should be adjusted according to age and severity of symptoms.

Medication Restrictions for Special Populations

Pregnant and lactating women: Use only when therapeutic benefits outweigh risks. Lactating women need to weigh discontinuing the drug or suspending breastfeeding.

Elderly patients: Due to age-related decline in physiological functions, dose reduction and monitoring of adverse reactions are required.

Children and patients with hepatic or renal insufficiency: Relevant data are not clearly stated in the current package insert; the necessity of use should be fully evaluated before administration.

Storage and Expiry Date Management

The medication should be stored at room temperature, avoiding moisture and direct sunlight.

The expiry date is 36 months; expired medications are strictly prohibited for use.

Note: For internal discussion among medical personnel only. For specific medication, please consult the attending physician. Drug information may change over time. For the latest information, we recommend adding a medical consultant or consulting for free online.
Recommended Articles
Dosage and Administration of Astomin (Dimemorfan Phosphate Tablets)
Astomin (Dimemorfan Phosphate Tablets) is a non-narcotic central antitussive. First approved in Japan in 1974, it has been widely used for relieving cough symptoms due to its high safety and low abuse...
Dosage and Administration of Xphozah (Tenapanor)
Xphozah (Tenapanor) is an FDA-approved sodium-hydrogen exchanger 3 (NHE3) inhibitor specifically indicated for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) undergoi...
What Are the Indications for Xphozah (Tenapanor)?
Xphozah (Tenapanor) is an innovative medication approved by the U.S. Food and Drug Administration (FDA), providing a new treatment option for serum phosphorus control in patients with chronic kidney d...
Purchase Channels for Xphozah (Tenapanor)
Xphozah (Tenapanor) is a sodium-hydrogen exchanger 3 (NHE3) inhibitor with tenapanor hydrochloride as the active ingredient. First approved in the United States in 2019, this medication is primarily u...
Purchase Channels for Xofluza (Baloxavir Marboxil)
Amid the current high incidence of respiratory diseases, the anti-influenza drug Xofluza (Baloxavir Marboxil) has garnered widespread attention due to the convenience of single oral administration. As...
What Are the Indications for Xofluza (Baloxavir Marboxil)?
Xofluza (Baloxavir Marboxil) is a novel anti-influenza virus drug. With its unique single-dose administration regimen and targeted mechanism of action, it provides an innovative option for influenza p...
Dosage and Administration of Xofluza (Baloxavir Marboxil)
Xofluza (Baloxavir Marboxil) is an innovative anti-influenza virus drug that exerts therapeutic effects with a single oral dose, demonstrating significant clinical advantages.Dosage and Administration...
What Are the Precautions for Using Xofluza (Baloxavir Marboxil)?
Xofluza (Baloxavir Marboxil) is a novel anti-influenza virus drug primarily used for the treatment and prevention of influenza A and B virus infections. As a prescription medication, its use must stri...
Related Articles
Dosage and Administration, Recommended Dose of Elacestrant (Orserdu)
Elacestrant (Orserdu) is a selective estrogen receptor degrader (SERD), which provides an important treatment option for patients with estrogen receptor-positive, HER2-negative advanced or metastatic ...
What Are the Indications for Elacestrant (Orserdu)?
Elacestrant (Orserdu) is a novel endocrine therapy agent that demonstrates significant value in the treatment of advanced breast cancer with specific gene mutations. As an estrogen receptor antagonist...
What Are the Purchase Channels for Elacestrant (Orserdu)?
With the advancement of medical technology, elacestrant (Orserdu), a targeted drug for breast cancer with specific gene mutations, has brought new treatment options for patients. As the first oral sel...
Adverse Reactions of Capmatinib (Tabrecta)
Capmatinib (Tabrecta) is a highly selective MET inhibitor indicated for the treatment of patients with advanced non-small cell lung cancer harboring MET gene mutations. By precisely inhibiting the act...
What are the Precautions for Capmatinib (Tabrecta) Administration?
Capmatinib (Tabrecta) is a targeted therapy drug for MET gene mutations, demonstrating significant efficacy in the treatment of advanced malignancies such as non-small cell lung cancer.What are the Pr...
Dosage and Administration, Recommended Dosage of Capmatinib (Tabrecta)
Capmatinib (Tabrecta) is a highly selective MET inhibitor, offering a precision treatment option for patients with metastatic non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutation...
What Are the Indications for Capmatinib (Tabrecta)?
Capmatinib (Tabrecta) is a targeted therapy medication that plays an important role in the treatment of non-small cell lung cancer associated with specific gene mutations. As a MET kinase inhibitor, i...
What Are the Purchase Channels for Capmatinib (Tabrecta)?
Capmatinib (Tabrecta) is a highly selective MET inhibitor that has demonstrated significant efficacy in patients with metastatic non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutat...
New Drugs
Infigratinib(Truseltiq)
Infigratinib(Truseltiq)
Treatment of previously treated, unresectable locally advanced or metastatic...
Opicapone(Ongentys)
Opicapone(Ongentys)
Adjunctive treatment to levodopa/carbidopa for reducing "off" episodes in...
Deflazacort(Emflaza)
Deflazacort(Emflaza)
Treatment of Duchenne muscular dystrophy (DMD) in patients aged 2 years and...
Faricimab-svoa(Vabysmo)
Faricimab-svoa(Vabysmo)
Treatment of neovascular age-related macular degeneration, diabetic macular...
Counselling Service
Global Drug Search
Clinical Research Recruitment
Overseas Medical Treatment
Remote Consultations
Note: Our medical consultant will contact you as soon as possible. We promise to strictly protect your privacy.
Submit
Business
  • Core products
  • Antitumor drugs
  • General drug
  • Antiviral drugs
  • Biological agents
Contact Us 
  • mailbox:info@lucius.la
Welcome to consult
ucius Pharmaceuticals (Lao) Co.,Ltd All rights reserved